» Articles » PMID: 19528441

Combination of PI3K/mTOR Inhibition Demonstrates Efficacy in Human Chordoma

Overview
Journal Anticancer Res
Specialty Oncology
Date 2009 Jun 17
PMID 19528441
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chordomas are rare tumors of the axial skeleton for which surgical resection remains the most reliable means of cure. PI-103 is a inhibitor of PI3K/AKT and mTOR activation. This study aims to determine whether the PI3K/mTOR pathway was active in chordomas and whether their inhibition could lead to decreased proliferation and increased apoptosis.

Materials And Methods: Thirteen human chordoma were tested for activation of the PI3K/mTOR pathway. The human chordoma cell line UCH-1 was treated with increasing doses of PI-103. Inhibition of AKT and mTOR was examined and assays assessing proliferation and apoptosis were performed.

Results: The chordoma specimen demonstrated activation of the PI3K/mTOR pathway. PI-103 inhibited the AKT and mTOR activation in the UCH-1 cell line. PI-103 inhibited proliferation and induced apoptosis in UCH-1.

Conclusion: The PI3K/AKT and mTOR signaling pathway is constitutively activated in chordoma. PI-103 decreases proliferation and induces apoptosis in the UCH-1 via inhibition of the PI3K/mTOR pathway.

Citing Articles

Targeting mTOR Pathway in PTEN Deleted Newly Isolated Chordoma Cell Line.

Pagani F, Gryzik M, Somenza E, Cominelli M, Balzarini P, Schreiber A J Pers Med. 2023; 13(3).

PMID: 36983607 PMC: 10056194. DOI: 10.3390/jpm13030425.


Advancement of PI3 Kinase Inhibitor Combination Therapies for PI3K-Aberrant Chordoma.

Heft Neal M, Michmerhuizen N, Kovatch K, Owen J, Zhai J, Jiang H J Neurol Surg B Skull Base. 2022; 83(1):87-98.

PMID: 35155075 PMC: 8824629. DOI: 10.1055/s-0040-1716694.


AZD8055 enhances in vivo efficacy of afatinib in chordomas.

Zhao T, Siu I, Williamson T, Zhang H, Ji C, Burger P J Pathol. 2021; 255(1):72-83.

PMID: 34124783 PMC: 9534552. DOI: 10.1002/path.5739.


Synergistic drug combinations and machine learning for drug repurposing in chordoma.

Anderson E, Havener T, Zorn K, Foil D, Lane T, Capuzzi S Sci Rep. 2020; 10(1):12982.

PMID: 32737414 PMC: 7395084. DOI: 10.1038/s41598-020-70026-w.


Rationale for the advancement of PI3K pathway inhibitors for personalized chordoma therapy.

Michmerhuizen N, Owen J, Heft Neal M, Mann J, Leonard E, Wang J J Neurooncol. 2020; 147(1):25-35.

PMID: 32067197 PMC: 7474463. DOI: 10.1007/s11060-020-03418-7.